Overview

TKI 258 in Von Hippel-Lindau Syndrome (VHL)

Status:
Terminated

Trial end date:
2015-12-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to learn if dovitinib can safely be given to patients who have VHL with a measurable hemangioblastoma (tumor of the central nervous system). The effects of this drug on the disease will also be studied.

Phase:

Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Novartis